Finding ways to lower the rebates paid by the pharmaceutical industry to the UK government and fostering partnerships to make the UK a more attractive launch market could help reduce the number of terminated technology appraisals conducted by NICE, the health technology appraisal institute, says the UK pharmaceutical industry.
Making the UK market more attractive would incentivize companies to submit evidence to Health technology appraisal body NICE. (Shutterstock)